Agios 制药
AGIO
31.32
-1.00
-3.09%
Agios 制药
US · AGIO
#2841 按市值排名
上市于 1970
31.32
-1.00
-3.09%
实时 - 追踪5344个代码 - 心跳于2秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 111.82% -0.31pp
- 机构数量
- 284
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund67.41%
Hedge Fund33.47%
Private Company4.39%
Public Company4.09%
VC/PE Fund1.31%
Individual/Insider1.11%
Insurance Company0.73%
Government Pension Fund0.42%
主要股东 截至 2026-06-30
BlackRock
10.81% · 6.46M 股
Farallon Capital Management, L.L.C.
9.91% · 5.92M 股
State Street Global Advisors
5.92% · 3.53M 股
Lynx1 Capital Management LP
5.71% · 3.41M 股
D. E. Shaw & Co., L.P.
5.20% · 3.11M 股
Vanguard Capital Management, LLC
5.16% · 3.08M 股
Vanguard Portfolio Management, LLC
4.85% · 2.90M 股
Armistice Capital LLC
4.02% · 2.40M 股
Erste Asset Management GmbH
3.61% · 2.15M 股
Macquarie Investment Management Business Trust
3.54% · 2.11M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 39次买入 · 11次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Brian Goff | Chief Executive Officer | 0.31% |
| Jacqualyn Fouse | Chair of the Board of Directors | 0.26% |
| Cecilia Jones | Chief Financial Officer | 0.09% |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 0.09% |
| James Burns | Corporate Secretary & Chief Legal Officer | 0.08% |
| Tsveta Milanova | Chief Commercial Officer | 0.08% |
| David Scadden | Independent Director | 0.03% |
| Maykin Ho | Independent Director | 0.03% |
| Cynthia Smith | Independent Director | 0.03% |
| Rahul Ballal | Independent Director | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-03 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Automatic Disposition | -30,000 | $30.48 |
| 2026-07-07 | Jay Backstrom | Director | Other Acquisition | +1,447 | -- |
| 2026-06-30 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -4,007 | $37.56 |
| 2026-06-30 | Sarah Gheuens | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Retained | +4,368 | -- |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Jacqualyn Fouse | Chair of the Board of Directors | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jeffrey Capello | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Jeffrey Capello | Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Kaye Foster-Cheek | Lead Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Jay Backstrom | Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Jay Backstrom | Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Maykin Ho | Independent Director | Other Derivative Acquisition | +2,927 | -- |
| 2026-06-17 | Maykin Ho | Independent Director | Other Derivative Acquisition | +14,950 | $34.16 |
| 2026-06-17 | Maykin Ho | Independent Director | Derivative Exercise and Retained | +2,816 | -- |
| 2026-06-17 | Brian Goff | Chief Executive Officer | Other Derivative Acquisition | +39,000 | -- |
| 2026-06-17 | Brian Goff | Chief Executive Officer | Other Derivative Disposition | -39,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Agios 制药 讨论区 0 条评论